Advertisement

Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial

      Purpose

      To determine the efficacy and durability of aflibercept used in a treat-and-extend (TAE) regimen for neovascular age-related macular degeneration (NVAMD).

      Design

      Multicenter, prospective, open label, noncomparative, interventional study.

      Methods

      Forty eyes of 40 patients with treatment-naïve NVAMD were managed with a TAE regimen of intravitreal aflibercept. The main endpoints were the change in mean and median best-corrected visual acuity from baseline at years 1 and 2. Other endpoints included mean number of annual injections and treatment intervals.

      Results

      Thirty-five (87.5%) and 31 patients (77.5%) completed year 1 and year 2, respectively. The mean letter gain was 7.2 (P < .001) and 2.4 (P = .269) letters at 1 and 2 years, respectively, from a mean baseline of 58.9 letters (20/63 Snellen equivalent). The median visual gain was 11.5 and 7.5 letters at 1 and 2 years, respectively, from a median baseline of 59.0 letters (20/63 Snellen equivalent). The mean number of injections was 8.0 and 6.5 during the first and second year, respectively. Twelve-week or longer treatment intervals were used in 35% and 38% of patients during the first- and second-year time points, respectively.

      Conclusion

      Intravitreal aflibercept TAE therapy led to significant visual improvement in eyes with NVAMD at 1 year, with some loss in the visual gains at the end of year 2 that was not related to loss of exudative control. TAE therapy with aflibercept is a rational strategy to reduce treatments and clinic evaluations over 2 years with satisfactory outcomes.
      To read this article in full you will need to make a payment

      References

        • Ferris 3rd, F.L.
        • Fine S.L.
        • Hyman L.
        Age-related macular degeneration and blindness due to neovascular maculopathy.
        Arch Ophthalmol. 1984; 102: 1640-1642
        • Brown D.M.
        • Kaiser P.K.
        • Michels M.
        • et al.
        Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1432-1444
        • Rosenfeld P.J.
        • Brown D.M.
        • Heier J.S.
        • et al.
        Ranibizumab for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1419-1431
        • Martin D.F.
        • Maguire M.G.
        • Ying G.S.
        • Grunwald J.E.
        • Fine S.L.
        • Jaffe G.J.
        Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
        N Engl J Med. 2011; 364: 1897-1908
        • Chakravarthy U.
        • Harding S.P.
        • Rogers C.A.
        • et al.
        Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
        Ophthalmology. 2012; 119: 1399-1411
        • Kodjikian L.
        • Souied E.H.
        • Mimoun G.
        • et al.
        Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial.
        Ophthalmology. 2013; 120: 2300-2309
        • Krebs I.
        • Schmetterer L.
        • Boltz A.
        • et al.
        A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
        Br J Ophthalmol. 2013; 97: 266-271
        • Heier J.S.
        • Brown D.M.
        • Chong V.
        • et al.
        Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
        Ophthalmology. 2012; 119: 2537-2548
        • Spaide R.F.
        The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
        Am J Ophthalmol. 2009; 148: 1-3
        • Freund K.B.
        • Korobelnik J.F.
        • Devenyi R.
        • et al.
        Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations.
        Retina. 2015; 35: 1489-1506
        • Gupta O.P.
        • Shienbaum G.
        • Patel A.H.
        • Fecarotta C.
        • Kaiser R.S.
        • Regillo C.D.
        A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
        Ophthalmology. 2010; 117: 2134-2140
        • Shienbaum G.
        • Gupta O.P.
        • Fecarotta C.
        • Patel A.H.
        • Kaiser R.S.
        • Regillo C.D.
        Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
        Am J Ophthalmol. 2012; 153: 468-473.e1
        • Rayess N.
        • Houston 3rd, S.K.
        • Gupta O.P.
        • Ho A.C.
        • Regillo C.D.
        Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.
        Am J Ophthalmol. 2015; 159: 3-8.e1
        • Oubraham H.
        • Cohen S.Y.
        • Samimi S.
        • et al.
        Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration.
        Retina. 2011; 31: 26-30
        • Arnold J.J.
        • Campain A.
        • Barthelmes D.
        • et al.
        Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration.
        Ophthalmology. 2015; 122: 1212-1219
        • Rahimy E.
        • Rayess N.
        • Ho A.C.
        • Regillo C.D.
        Treatment outcomes for neovascular age-related macular degeneration patients with initial vision better than 20/40 using a treat-and-extend regimen.
        Retina. 2015; 36: 875-880
        • Berg K.
        • Hadzalic E.
        • Gjertsen I.
        • et al.
        Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study treat-and-extend protocol: two-year results.
        Ophthalmology. 2016; 123: 51-59
        • Abedi F.
        • Wickremasinghe S.
        • Islam A.F.
        • Inglis K.M.
        • Guymer R.H.
        Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years.
        Retina. 2014; 34: 1531-1538
        • Toalster N.
        • Russell M.
        • Ng P.
        A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration.
        Retina. 2013; 33: 1351-1358
        • Berg K.
        • Pedersen T.R.
        • Sandvik L.
        • Bragadottir R.
        Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
        Ophthalmology. 2014; 122: 146-152
        • Wykoff C.C.
        • Croft D.E.
        • Brown D.M.
        • et al.
        Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results.
        Ophthalmology. 2015; 122: 2514-2522
        • Barthelmes D.
        • Campain A.
        • Nguyen P.
        • et al.
        Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
        Br J Ophthalmol. 2016; 100: 1640-1645
        • Homer N.
        • Grewal D.S.
        • Mirza R.G.
        • Lyon A.T.
        • Gill M.K.
        Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
        Eye (Lond). 2015; 29: 1152-1155
        • Stewart M.W.
        • Rosenfeld P.J.
        Predicted biological activity of intravitreal VEGF Trap.
        Br J Ophthalmol. 2008; 92: 667-668
        • Schmidt-Erfurth U.
        • Kaiser P.K.
        • Korobelnik J.F.
        • et al.
        Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
        Ophthalmology. 2014; 121: 193-201
        • Grunwald J.E.
        • Pistilli M.
        • Daniel E.
        • et al.
        Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials.
        Ophthalmology. 2017; 124: 97-104
        • Rofagha S.
        • Bhisitkul R.B.
        • Boyer D.S.
        • Sadda S.R.
        • Zhang K.
        Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
        Ophthalmology. 2013; 120: 2292-2299
        • Maguire M.G.
        • Martin D.F.
        • Ying G.S.
        • et al.
        Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials.
        Ophthalmology. 2016; 123: 1751-1761
        • Peden M.C.
        • Suner I.J.
        • Hammer M.E.
        • Grizzard W.S.
        Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
        Ophthalmology. 2015; 122: 803-808
        • Jaffe G.J.
        • Kaiser P.K.
        • Thompson D.
        • et al.
        Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid.
        Ophthalmology. 2016; 123: 1856-1864
        • Waldstein S.M.
        • Simader C.
        • Staurenghi G.
        • et al.
        Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials.
        Ophthalmology. 2016; 123: 1521-1529
        • Toth C.A.
        • Decroos F.C.
        • Ying G.S.
        • et al.
        Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the Comparison of Age-Related Macular Degeneration Treatments Trials.
        Retina. 2015; 35: 1303-1314
        • Stone T.W.
        ASRS Preferences and Trends (PAT) Survey.
        American Society of Retinal Specialists, 2016 (Available at: http://www.asrs.org/content/documents/_asrspatslides2016finalsm.pdf, Accessed November 22, 2016)

      Linked Article